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Mammary gland hyperplasia (MGH) is very common, especially among young 
and middle-aged women. New diagnostics and biomarkers for MGH are needed for 
rational clinical management and precision medicine. We report here new findings 
using a glycomics approach, with a focus on immunoglobulin G (IgG) N-
glycosylation. A cross-sectional study was conducted in a community-based 
population sample in Beijing, China. We recruited 387 women, aged 40-65 years for 
the present study. IgG N-glycans were characterized in the serum by 
ultra-performance liquid chromatography. The prevalence of MGH in our study 
sample was 47%. The levels of the glycan peaks (GPs) GP2, GP5, GP6 and GP7 were 
lower in the MGH group compared to the control group, while GP14 was significantly 
higher in the MGH group (P < 0.05). A predictive model using GP5, GP21 and age 
was established and a receiver operating characteristic (ROC) curve analysis was 
performed. The sensitivity and specificity of the model for MGH was 61.3% and 
63.2%, respectively, likely owing to receptor mechanisms and/or inflammation 
regulation. To the best of our knowledge, this is the first study reporting on an 
association between IgG N-glycosylation and MGH. We suggest person-to-person 
variations in IgG N-glycans and their combination with multi-omics biomarker 
strategies offer a promising avenue to identify novel diagnostics and individuals at 
increased risk of MGH. 
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Mammary gland hyperplasia (MGH), also called breast hyperplasia or breast 
dysplasia, is one of the most common disorders among women, and accounts for over 
70% of all breast diseases (Li et al., 2018). Although the causes of MGH are not fully 
understood, it is known to be closely related to endocrine disorders (Chen et al., 
2015).  
 
Potential pathogenetic contributions to the onset of MGH include (Arendt et al., 
2015; Samoli et al., 2013; Li et al., 2017):  
1) an imbalance between estrogen (E2) and progesterone (P) (i.e., decreased 
progesterone secretion, increased estrogen concentration;  
2) aberrant expression and distribution of E2 receptors in breast parenchyma and 
mesenchymal tissue; and  
3) increased prolactin (PRL) related to the development of the mammary gland.  
 
Glycosylation, a mechanism for the post-translational modification in biology, 
affects 90% of mammalian proteins by enabling various biological functions (Mechref 
et al., 2011). However, abnormal glycosylation or deglycosylation are associated with 
specific disorders (Zoldoš et al., 2013; Liu et al., 2018). Immunoglobulin G (IgG), a 
glycosylated molecule, accounting for about 75% of serum immunoglobulins, plays 
an important role in regulation of the inflammatory response (Masuda et al., 2007; 
Vučković et al., 2015; Sebastian et al., 2016). The structure of IgG consists of two 
parts: a fragment of antigen binding (Fab) with specific antigen-binding activity, and a 
crystalline fragment (Fragment crystallizable, Fc) that binds to effector molecules or 
effector cells. The function of IgG can be significantly interfered by aberrant N-
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glycans at Fc segment, which can lead to inflammatory diseases, metabolic-related 
disorders, autoimmune diseases or carcinomas (Liu et al., 2018; Sebastian et al., 2016; 
Ravetch et al., 2001; Russell et al., 2017).  
 
Omics technologies, including glycomics, can provide quantitative features of the 
profiles of post-translational modification of proteins, which might have a wide-range 
application in predictive diagnostics, targeted prevention and personalization of 
medical services (Lu et al., 2018). To the best of our knowledge, no studies have so 
far analyzed the relationship between MGH and IgG N-glycosylation.  
 
This study aimed to identify the N-glycans profiles of IgG for individuals with 
MGH, and to assess the effect of IgG N-glycosylation with an eye to the development 
of MGH in a community-based population.  
 
Materials and Methods 
Study participants 
Between November 2011 and February 2012, we randomly recruited 387 women 
participants from urban communities in Beijing, China.  
Inclusion criteria were:  
1) women aged 40 to 65 years,  
2) no history of breast diseases, and 
3) no history of medication in the past two weeks.  
 
Exclusion criteria were:  
1) pregnant and lactating women,  
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2) participants with severe mental disorders, or  
3) individuals with other serious physical illness.  
 
This study was approved by the ethics committee of Capital Medical University 
(No. 2009SY16). Each participant signed a written informed consent before 
enrollment.  
 
MGH was diagnosed in accordance with the Diagnosis and Treatment of Breast 
Diseases of China (Chen et al., 2015): 1) Breast lumps were detected in one or two 
sides of breast with ultrasonography, and fibroadenoma, fat necrosis, or lipoma were 
excluded by clinicians; 2) For patients with nipple discharge, ductoscopy or 
galactography combined with cytology were used for differential diagnosis; 3) In the 
case of malignant lesions suspected by ultrasonic examination or molybdenum target 
X-ray examination, the diagnosis was confirmed by histopathological examination; 4) 
physiologic hyperplasia was excluded by clinicians. 
 
Clinical measurements 
Clinical measurements were carried out using standardized techniques (Yu et al., 
2016; Liu et al., 2018). Body mass index (BMI) was calculated by the ratio of weight 
(kg) / height squared (m2). Peripheral blood was collected from each participant after 
an overnight fast, and then stored in an Ethylenediaminetetraacetic acid (EDTA)-anti-
coagulated tube. Fasting blood glucose (FBG), serum high-density lipoprotein 
cholesterol (HDL), low-density lipoprotein cholesterol (LDL), triglycerides (TG), 
total cholesterol (TC), urea, uric acid, creatinine (Cre), carcinoembryonic antigen 
(CEA), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were 
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assayed. All physical examinations and clinical diagnosis were performed at the 
Beijing Xuanwu Hospital of the Capital Medical University. 
 
IgG N-glycans analyses 
IgG N-glycans in serum samples were isolated and initially analyzed by 
hydrophilic interaction liquid chromatography (Waters Corp., Milford, MA, USA) 
with ultra high-performance liquid chromatography (HILIC-UPLC) (Menni et al., 
2013). The level of each glycan was measured by a specific glycan peak (GP) 
detected in HILIC-UPLC assay. The detailed methods were described previously 
(Adua et al., 2017; Hou et al., 2019; Novokmet et al., 2014).  
 
Statistical analyses 
All statistical analyses were performed with SPSS 25.0 (IBM, Armonk, NY, 
USA). Kolmogorov-Smirnov test was utilized to examine whether the glycan 
measurements showed a statistically normal distribution. Because these data were not 
normally distributed, median (M) and interquartile range (IQR) were computed for 
descriptive statistics. A non-parametric statistical method (Mann-Whitney U test) was 
carried out for between-group comparisons. Other quantitative data that were 
normally distributed were compared by Student’s t-test. Chi-squared test was used for 
comparisons of qualitative data. A multiple logistic regression analysis was 
undertaken to establish the classification model by screening the positive glycan 
biomarkers for MGH diagnosis. Then a receiver operating characteristic (ROC) curve 






Description of study participants 
A total of 387 participants were enrolled in this study, including 194 women with 
MGH (cases) and 193 women who had no MGH (controls). All participants had a 
history of pregnancy and birth. The prevalence of MGH was 47.0%. We stratified all 
participants into four groups according to BMI levels.  
As shown in Table S1, the prevalence rates of MGH were 37.5% in the 
underweight group, 53.1% in the normal weight group, 45.5% in the overweight 
group and 55.0% in the obese group. There were no significant differences between 
groups.  
Demographic and clinical results are shown in Table 1. The age of individuals 
with MGH ranged from 40 to 64 years (mean age 46.25 years), which was statistically 
and slightly lower than that of the controls (range 40-65 years, mean age 47.87 years). 
No between-group differences were statistically significant for BMI, FBG, HDL, 
LDL, TG, TC, urea, uric acid, Cre, CEA, AST, and ALT.  
 
Descriptive statistics for the glycans and derived traits 
For the 24 IgG N-glycans detected by HILIC-UPLC, one glycan (GP3) was not 
include in our analyses because it did not pass the quality control standard (shown in 
Figure S1). Fifty-four derived glycan traits were calculated with the initial glycans 
(Adua et al., 2017; Hou et al., 2019).  
As shown in Table 2, five initial glycans and five derived traits were significantly 
different between the MGH group and the control group (P<0.05). For five initial 
glycans, the levels of GP2, GP5, GP6 and GP7 were lower in the MGH group than in 
the control group, while GP14 was significantly higher in MGH group (P<0.05). 
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Among the derived traits, two derived traits (G2n and FG1n total/G1n) were higher in the 
MGH group, and three [FBStotal/FStotal, G0n and BG2n/(FG2n+FBG2n)] were higher in 
the control group (P < 0.05). 
 
Classification of MGH using IgG N-glycans 
Using univariate logistic regression analyses, we identified whether each of IgG 
N-glycans was associated with the development MGH (Table S2). GP2, GP5, GP6 
and GP14 were significantly associated with MGH. With regard to the derived glycan 
traits, FBStotal/FStotal, G0n, G2n, FG2n/(BG2n+FBG2n) and BG2n/(FG2n+FBG2n) were 
associated with MGH. 
To evaluate whether IgG N-glycans contributed to distinguishing individuals with 
MGH from healthy women, we established a classification model of MGH by a 
multivariate logistic regression analysis. As shown in Table 3 and Figure S2, two 
glycans (GP5 and GP21) and age were included in this model, where BMI, FBG, 
HDL, LDL, TG, TC, urea, uric acid, Cre, CEA, AST, and ALT were adjusted. 
The ROC curve analysis was applied to evaluate the value of this model in the 
classification of MGH. As shown in Figure 1, the area under the curve (AUC) was 
0.653 (95% CI: 0.598-0.707). This result indicates that the classification model could 
distinguish individuals with MGH from healthy persons. The cut-off value of 0.224 
was used to distinguish breast hyperplasia. The sensitivity and specificity were 61.3% 
and 63.2%, respectively. 
 
Discussion 
Our findings revealed a high prevalence rate (47.0%) of MGH in a high-risk 
population. In addition, we found that IgG N-glycan profiles were significantly 
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associated with MGH. The serum levels of the five initial and seven derived traits of 
glycans differed between the MGH group and healthy individuals. Although the 
sensitivity and specificity of the predictive association is not at the level of a 
diagnostic for routine clinical use at this time, our findings point to the promise of 
glycomics, especially if it is combined as a postgenomic biomarker discovery 
platform with other multi-omics approaches in the future (Kunej, 2019; Liu et al. 
2019; Pirih and Kunej, 2017). 
 
MGH is a common breast disease among women (Zhao et al., 2018), which leads 
to significant morbidity. Clinical diagnosis of MGH would benefit from novel 
biomarkers (Li et al., 2017). Studies have reported 52% to 55% women of 
childbearing age are affected by MGH in China, which is similar to our findings in the 
present study (Jiang et al., 2011).  
The growth and differentiation of normal mammary epithelial cells are regulated 
by many biological mechanisms, one of which is the hypothalamic-pituitary-gonadal 
axis that modulates the proliferation of mammary gland tissue and the menstrual cycle 
(Li et al., 2017). As a target organ of hormone action, the breast gland reacts to several 
hormones, including E2, P, and PRL (O'Leary et al., 2017; Stingl et al., 2011). 
Endocrine disorder that causes dysregulation is one of the notable determinants of the 
development of MGH. E2 and P can also indirectly regulate normal mammary gland 
development by paracrine signaling (Anderson et al., 2004).  
 
E2 and P are lipophilic steroid hormones that are synthesized periodically by 
ovaries under the control of pituitary gonadotropin, and transferred to target organs 
through circulating blood (O'Leary et al., 2017; Anderson et al., 2004). E2 can 
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promote the proliferation of mammary epithelial cells and the growth of mammary 
ducts. P upregulates the further development and maturation of mammary acinar, and 
also inhibits the response of mammary gland to E2 (Samoli et al., 2013; Arendt et al., 
2015). The absolute or relative over-secretion of E2 and lack of P leads to an 
imbalance between E2 and P, resulting in excessive proliferation and sub-involution of 
breast parenchyma (Li et al., 2017).  
 
PRL not only contributes to the growth, development and maintenance of breast 
feeding, but also affects the function of the hypothalamic-pituitary-gonad axis 
(Brisken et al., 1999). In addition, PRL stimulates the production of E2 and inhibits 
the secretion of P in the luteal phase, thus contributing to the excessive proliferation 
of breast tissue (Oakes et al., 2008). PRL, together with E2 and P, regulates the growth 
of mammary epithelial cells. 
 
For healthy women, the levels of E2 and P change periodically in accordance with 
the menstrual cycle, acting as nuclear transcription factors by binding with estrogen 
receptor (ER)-α and progesterone receptor (PR) (Stingl et al., 2011; Lee et al., 2006). 
The E-ER or P-PR complex enters the nucleus from cytoplasm, regulates transcription 
of target DNA, and modulates the growth, division and metabolism of target cells 
(i.e., mammary epithelial cells, ducts and acinar tissues) (Lee et al., 2006). ER and PR 
are proteins modified by glycosylation. N-glycosylation of Asn44 at the G protein-
coupled estrogen receptor is critical for the maturation and activation of the ER 
receptor (Gonzalez et al., 2019). The glycosylation of ER-α at S573 is important for 
protein stability and nuclear localization of this receptor (Deng et al., 2018). The 
abnormal glycosylation of ER and PR might influence their sensitivity for coupling to 
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E2 and P, which might induce the development of MGH (Li et al., 2017). 
 
Inflammatory diseases, metabolic-related disorders, autoimmune diseases and 
carcinomas have also been reported to be related to aberrant glycosylation, where N-
glycans of IgG at Fc segment play an important role in the regulation of the balance 
between inflammation and anti-inflammation (Russell et al., 2017). In spite of 
abnormal glycosylation of ER and PR, glycosylation might contribute to MGH in a 
pathogenetic pathway of IgG-related inflammation regulation. Mammary gland is a 
self-renewing tissue in which the morphology and differentiation change cyclically 
during menstruation, pregnancy, and lactation (Zhang et al., 2011).  
 
Studies have found that adipocyte enhancer-binding protein-1 (AEBP-1) is a 
transcriptional regulator of macrophage cholesterol homeostasis and macrophage 
inflammatory responsiveness (He et al., 1995; Majdalawieh et al., 2010; Majdalawieh 
et al., 2010). AEBP-1 regulates mammary epithelial cell growth by regulation of 
nuclear factor (NF)-B activity in the mammary epithelium (Holloway et al., 2012). 
NF-B regulates the expression of pro-inflammatory chemokines and cytokines, 
ultimately promoting proliferation of mammary epithelial cells (Majdalawieh et al., 
2006; Majdalawieh et al., 2007).  
 
This inflammatory process might be regulated by IgG, as well impacted by IgG 
N-glycosylation. N-glycosylation on the Fc segment plays a pivotal role in the 
structure and function of IgG. Aberrant IgG N-glycans bias the anti-inflammatory and 
pro-inflammatory function of IgG (Ren et al., 2016). Increased terminal glycosylation 
of IgG Fc leads to increased binding of the antibody to FcγRIIB, thereby resulting in 
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upregulation of anti-inflammatory activity (de Jong et al., 2016).  
 
We hypothesize that the inflammatory process of MGH might be related to 
glycosylation modification of IgG. However, the specific mechanism of action needs 
to be verified by experiments. Meanwhile, studies have reported that MGH can lead to 
inflammatory conditions, which means that the relationship between MGH and 
activation of inflammation is complex and needs to be explored further (Kuo et al., 
2007). 
 
Strengths and limitations 
To the best of our knowledge, this is the first study reporting on an association 
between IgG N-glycosylation and MGH. The findings provide new insights into the 
pathogenesis of MGH. However, some limitations should be considered: First, as this 
was a cross-sectional study, our results cannot fully address the causal relationship 
between IgG glycome and MGH. Second, the moderate sample size limits the 
generalization of the conclusions. Third, the relationship between MGH and IgG 
glycome might be biased by environmental determinants that were not evaluated in 
this study. Therefore, the effects of IgG N-glycans on MGH may be underestimated or 
overestimated. Nevertheless, we present here a new putative pathogenetic factor of 
MGH based on glycomics. However, we present a new clue to investigate the etiology 
of MGH from the viewpoints of glycosylation of estrogen- and progesterone- 
receptors and inflammation regulation of IgG. 
 
Conclusion 
Person-to-person variations in IgG N-glycans and their combination with multi-
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omics biomarker discovery strategies offer a promising avenue to identify novel 
diagnostics and individuals at increased risk of MGH. 
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AEBP-1 Adipocyte enhancer-binding protein-1 
ALT Alanine aminotransferase 
AST Aspartate aminotransferase 
BMI Body mass index 
CEA Carcinoembryonic antigen 
Cre Creatinine 
E2 Estrogen 
EDTA Ethylenediaminetetraacetic acid 
ER Estrogen receptor 
Fab Fragment of antigen binding 
FBG Fasting blood glucose 
Fc Fragment crystallizable 
GP Glycan peak 
HDL High-density lipoprotein cholesterol 
HILIC Hydrophilic interaction liquid chromatography 
IgG Immunoglobulin G 
IQR Interquartile range 
LDL Low-density lipoprotein cholesterol 
M Median 
MGH Mammary gland hyperplasia 
NF Nuclear factor 
P Progesterone 
PR Progesterone receptor 
PRL Prolactin 
ROC Receiver operating characteristic 
TC Total cholesterol 
TG Triglycerides 





Table 1 Characteristics of study participants 
Variables Cases (n=194) Controls (n=193) t/2 P-value 
Age 46.254.71 47.874.73 3.370 0.001 
Height 159.855.24 159.525.51 0.594 0.553 
Weight 61.578.05 61.298.62 0.333 0.740 
BMI 24.103.01 24.083.24 0.057 0.955 
Serum TC 5.050.83 5.180.98 1.399 0.163 
Serum HDL 1.700.30 1.750.40 1.196 0.233 
Serum LDL 2.720.65 2.800.74 1.177 0.240 
Serum TG 1.210.79 1.261.17 0.582 0.561 
FBG 5.180.55 5.180.74 0.027 0.978 
Urea 
4.961.03 4.841.16 1.094 0.275 
Uric acid 
218.3154.42 220.6555.66 0.419 0.676 
Cre 
49.856.15 50.266.75 0.630 0.529 
CEA 
1.320.65 1.481.24 1.621 0.106 
AST 
19.836.80 20.679.40 1.018 0.310 
ALT 
18.7711.47 19.2111.96 0.369 0.713 
Data are shown as mean ± standard deviation 
Mann–Whitney U-test: Age, BMI, TC, TG, HDL, LDL, FBG, Cre, CEA, AST, ALT;  
BMI body mass index, TC total cholesterol, TG triglycerides, HDL high-density lipoprotein 
cholesterol, LDL low-density lipoprotein cholesterol, FBG fasting blood glucose, Cre Creatinine, 
CEA carcinoembryonic antigen, AST aspartate aminotransferase, ALT alanine aminotransferase 
















GP1 0.05(0.04,0.08)  0.06(0.04,0.09)  35984.0 0.131 
GP2 0.27(0.19,0.39)  0.32(0.22,0.42)  34869.0 0.012 
GP4 13.92(11.76,17.01)  14.56(12.04,18.07)  35768.5 0.090 
GP5 0.22(0.18,0.26)  0.24(0.20,0.28)  33921.0 0.001 
GP6 3.39(2.85,3.91)  3.55(3.04,4.40)  34923.0 0.014 
GP7 0.53(0.40,0.69)  0.59(0.42,0.73)  35459.5 0.048 
GP8 18.44(17.13,19.40)  18.52(17.32,19.60)  36980.5 0.551 
GP9 9.60(8.77,10.77)  9.65(8.86,10.37)  36756.0 0.533 
GP10 4.83(4.29,5.52)  4.90(4.43,5.45)  37010.5 0.570 
GP11 0.66(0.56,0.74)  0.66(0.60,0.73)  36225.5 0.200 
GP12 1.00(0.71,1.39)  1.02(0.72,1.34)  37147.0 0.789 
GP13 0.47(0.40,0.55)  0.49(0.41,0.59)  36671.0 0.380 
GP14 19.83(17.59,21.61)  18.71(16.26,20.96)  34276.5 0.004 
GP15 2.05(1.74,2.36)  1.96(1.74,2.28)  36160.0 0.244 
GP16 3.08(2.71,3.38)  3.07(2.75,3.40)  37060.5 0.601 
GP17 1.00(0.85,1.19)  1.05(0.87,1.23)  36865.5 0.484 
GP18 13.25(11.36,14.90)  12.58(10.87,14.70)  35788.5 0.133 
GP19 1.83(1.64,2.04)  1.89(1.68,2.11)  35969.0 0.130 
GP20 0.33(0.29,0.41)  0.35(0.27,0.44)  36735.0 0.413 
GP21 0.67(0.55,0.77)  0.69(0.59,0.79)  35981.0 0.132 
GP22 0.09(0.07,0.12)  0.10(0.08,0.12)  36042.5 0.146 
GP23 1.72(1.33,2.10)  1.67(1.33,2.14)  37166.0 0.802 
GP24 1.50(1.25,1.84)  1.56(1.31,1.91)  36334.0 0.237 
FGS/(FG+FGS) 26.93(25.02,29.56)  27.04(24.88,29.77)  37405.5 0.974 
FBGS/(FBG+FBGS) 31.08(27.76,34.73)  30.73(27.96,35.03)  37163.5 0.668 
FGS/(F+FG+FGS) 22.23(19.87,24.87)  22.15(19.10,24.68)  36609.0 0.449 
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FBGS/(FB+FBG+FBGS) 23.77(20.93,26.75)  23.15(20.44,27.08)  37080.5 0.742 
FG1S1/(FG1+FG1S1) 9.93(8.61,10.90)  9.86(8.73,11.12)  37102.5 0.628 
FG2S1/(FG2+FG2S1+FG2S2) 38.34(35.81,40.48)  38.61(36.13,40.56)  36691.0 0.390 















FtotalS1/FtotalS2 5.49(4.71,6.40)  5.44(4.49,6.44)  36066.5 0.211 
FS1/FS2 9.37(8.01,11.00)  9.28(7.69,11.18)  36935.0 0.645 
FBS1/FBS2 1.20(1.05,1.37)  1.17(1.03,1.37)  36668.0 0.482 
FBStotal/FStotal 0.19(0.17,0.22)  0.19(0.17,0.23)  35438.0 0.046 
FBS1/FS1 0.11(0.10,0.14)  0.12(0.10,0.15)  35555.0 0.059 
FBS1/(FS1+FBS1) 0.10(0.09,0.12)  0.11(0.09,0.13)  35555.5 0.059 
FBS2/FS2 0.90(0.79,1.02)  0.92(0.83,1.06)  35745.0 0.086 
FBS2/(FS2+FBS2) 0.47(0.44,0.50)  0.48(0.45,0.51)  35745.0 0.086 
G0n 23.46(20.17,27.00)  24.65(20.83,29.52)  35216.0 0.028 
G1n 45.21(43.90,46.47)  45.17(43.80,46.62)  37198.0 0.824 
G2n 31.00(27.12,34.99)  29.64(24.60,33.60)  34974.0 0.025 
Fn total 96.68(95.86,97.32)  96.46(95.69,97.26)  35976.5 0.183 
FG0n total/G0n 98.48(97.92,98.90)  98.32(97.74,98.81)  35482.5 0.075 
FG1n total/G1n 98.48(98.00,98.81)  98.33(97.81,98.75)  35272.5 0.049 
FG2n total /G2n 93.59(92.35,94.47)  93.09(91.94, 94.33)  35644.5 0.102 
Fn 81.76(79.92,83.51)  81.56(80.08,82.79)  36057.0 0.208 
FG0n/G0n 79.02(76.65,81.84)  78.99(76.65,80.86)  36704.0 0.502 
FG1n/G1n 81.95(80.12,84.14)  81.92(80.25,83.43)  36775.5 0.545 
FG2n/G2n 84.18(82.88,85.90)  83.86(82.26,85.26)  35385.0 0.062 
FBn 14.67(13.08,16.21)  14.78(13.72,16.18)  36282.0 0.218 
FBG0n/G0n 19.21(17.09,21.44)  19.23(17.62,21.17)  37124.5 0.642 
26 
 
FBG1n/G1n 16.11(14.32,18.07)  16.03(14.86,18.20)  37121.5 0.640 
FBG2n/G2n 9.12(7.98,10.13)  9.10(8.26,10.11)  36459.0 0.285 
FBn/Fn 0.18(0.16,0.20)  0.18(0.17,0.20)  36287.0 0.220 
FBn/Fn total 15.16(13.47,16.78)  15.39(14.33,16.77)  36287.0 0.220 
Fn/(Bn + FBn) 5.29(4.78,6.09)  5.26(4.80,5.72)  36122.0 0.230 
Bn/(Fn + FBn) 6.52(5.39,7.57)  6.60(5.51,8.13)  36804.0 0.450 
FBG2n/FG2n 0.11(0.09,0.12)  0.11(0.10,0.12)  36353.0 0.244 
FBG2n/(FG2n+FBG2n ) 9.69(8.60,10.87)  9.85(8.97,10.79)  36353.0 0.244 
FG2n/(BG2n+FBG2n) 7.61(6.72,8.44)  7.33(6.67,8.03)  35465.5 0.072 
BG2n/(FG2n+FBG2n) 21.49(19.33,25.14)  23.63(19.89,28.42)  34587.5 0.006 
FGS/(FG+FGS) 26.93(25.02,29.56)  27.04(24.88,29.77)  37405.5 0.974 





Table 3 Multiple logistic regression analyses of the association of glycans with MGH 
Variables B SE Walds P-value OR 95% CI of OR 
      LCI UCI 
Age -0.064 0.023 7.492 0.006 0.938 0.896 0.982 
GP5 -3.630 1.592 5.201 0.023 0.027 0.001 0.600 
GP21 -1.318 0.669 3.874 0.049 0.268 0.072 0.995 
B, regression coefficient; SE, standard error; OR, odds ratio; CI, confidence interval; LCI, lower 





Figure 1 Receiver operating characteristic (ROC) curve analyses 
AUC, area under the curve; Model, the classification model of GP5, GP21 and age 
 
